Mode
Text Size
Log in / Sign up
N/A N=350 Randomized Single-blind Supportive Care

Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies

Non-small Cell Lung Cancer · Small Cell Lung Cancer · Mesothelioma · Esophageal Cancer · Gastric Cancer

Enrolled (actual)
350
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcome: Primary: Functional Assessment of Cancer Therapy (Quality of Life Measure) — 81.10; 77.70 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
early palliative care (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Apr 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Functional Assessment of Cancer Therapy (Quality of Life Measure)
81.26; 75.90
SECONDARY
Functional Assessment of Cancer Therapy (Quality of Life Measure)
81.26; 75.90
SECONDARY
Rate of Clinically Significant Depression Symptoms Based on Hospital Anxiety and Depression Scale
29; 32; 24; 32
SECONDARY
Number and Percentage of Participants Who Reported Goal of Their Cancer Treatment is to Cure Their Cancer
41; 50; 37; 32
SECONDARY
Family Caregiver Quality of Life as Measured by the SF-36
52.94; 51.40; 47.00; 45.92; 52.71; 53.22
SECONDARY
Family Caregiver Psychological Distress (Based on the Hospital Anxiety and Depression Scale)
9.02; 10.48; 9.82; 10.72
SECONDARY
Number and Percentage of Family Caregivers Who Reported the Goal of Treatment is to Cure Cancer
34; 40; 19; 29
SECONDARY
Coping (Brief Cope)
0.21; -0.88

Summary

The purpose of this study is to compare two types of care - standard oncology care and standard oncology care with early palliative care (started soon after diagnosis) to see which is better for improving the experience of patients and families with advanced lung and non-colorectal GI cancer. The study will use questionnaires to measure patients' and caregivers' quality of life, mood, coping and understanding of their illness.

Eligibility Criteria

Inclusion Criteria

  • Confirmed metastatic lung cancer (NSCLC, small cell lung cancer, and mesothelioma)or non-colorectal GI cancer (esophageal, gastric and hepatobiliary) not being treated with curative intent
  • Informed of metastatic disease within the previous 8 weeks
  • No prior therapy for metastatic disease
  • Able to read questions in English or willing to complete questionnaires with the assistance of an interpreter
  • Relative or friend of patient who will likely accompany the patient to clinic visits

Exclusion Criteria

  • Significant psychiatric or other co-morbid disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01401907). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search